Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 25c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $225.92 --0%
EPS Growth %: +174.9%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: +174.9%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $6.64, $0.25 better than the analyst estimate of $6.39. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.16 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised
- Abbvie (ABBV) Reiterated at Overweight by Cantor Fitzgerald after Analyst Call
- Pfizer (PFE) Reiterated at Neutral by Cantor Fitzgerald on Negative SV Data
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
